Opendata, web and dolomites

ONCO-VAX SIGNED

A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCO-VAX project word cloud

Explore the words cloud of the ONCO-VAX project. It provides you a very rough idea of what is the project "ONCO-VAX" about.

lysis    cancer    paradigm    local    backbone    oncolytic    limited    treating    malignancy    synergistic    immunity    cell    spread    therapy    inherently    epidemiologically    tumor    medical    multifaceted    systemic    gene    optimized    vax    intratumoral    life    stimulatory    hepatocellular    oncology    ovs    liver    express    additional    suppressive    dramatic    directed    heavy    treat    ov    patients    worldwide    immuno    therapeutic    mechanism    capacity    immunotherapy    platform    patient    basis    subset    viruses    shift    antiviral    health    combination    stimulating    eradicating    carcinoma    mass    dendritic    monotherapeutics    disease    hcc    multimodal    direct    innate    vaccine    antitumor    utilized    decades    strategy    enhanced    broad    metastatic    initiate    successful    solid    microenvironment    edge    employ    innovative    disappointing    layer    potentially    burden    combat    financially    replication    cutting    reaching    onco    despite    nevertheless    tumors    elegant    virus    societal    spreading    imposes    combined    chimeric    intensive    immune    scheme    transforming    restricts   

Project "ONCO-VAX" data sheet

The following table provides information about the project.

Coordinator
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙988 €
 EC max contribution 1˙499˙988 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 1˙499˙988.00

Map

 Project objective

Despite many decades of intensive research, cancer remains a major worldwide health concern and imposes a heavy societal burden, both epidemiologically and financially. Cancer immunotherapy is rapidly transforming the face of medical oncology as an exciting paradigm shift in treating cancer by exploiting the immune system of the patient as the basis for the therapy. Although dramatic results have been achieved in a subset of patients, the responses in most solid tumors have been disappointing. Hepatocellular carcinoma (HCC) represents a particularly challenging malignancy to treat, due to the inherently immune-suppressive microenvironment in the liver. Oncolytic viruses (OVs) offer an elegant multimodal approach to combat HCC through their ability to cause direct tumor cell lysis, while stimulating immune responses directed against the tumor. Nevertheless, the potential of OVs as monotherapeutics is limited by the innate antiviral immune response, which rapidly restricts virus replication and spread within the tumor mass. Therefore, a successful therapeutic strategy should employ a combination scheme involving a mechanism to improve the intratumoral dissemination of the OV, while exploiting the immune-stimulatory capacity of the virus, in order to achieve far-reaching synergistic responses that can target metastatic disease. The ONCO-VAX approach aims to accomplish just that. A novel chimeric oncolytic virus backbone with an enhanced cell-cell spreading capacity, will be utilized as a platform to express an optimized gene for eradicating the local immune-suppressive microenvironment in the tumor. As an additional layer of therapy, the virus will be combined with a cutting edge dendritic cell vaccine approach to initiate a broad antitumor response for systemic and potentially life-long immunity against the cancer. This multifaceted approach represents an innovative and crucial step forward in the rapidly evolving field of cancer immuno-oncology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCO-VAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCO-VAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More